The Center for Health Economics and Policy (CHEP) pilot program announces funding for two projects in the inaugural round of funding from CHEP. The funding for these year-long projects begins on September 1, 2016.
Correlates of Enactment of State Legislation Related to HPV Vaccines
Human Papillomavirus (HPV) is the most common sexually transmitted infection in the United States. In addition to causing genital warts, certain strains of HPV cause cell damage leading to cervical and other cancers in men and women. Vaccines for HPV have been approved since 2006 and have high efficacy for prevention of HPV infection. However, vaccine uptake for the target population of adolescent and young adults is significantly lower than national targets. Policies at the state level can impact HPV vaccine uptake through vaccine requirements, education, or funding, but support for such legislation varies.
The purpose of this project is to explore trends and correlates of enactment of state HPV vaccine legislation from 2006-2016. Findings can inform public health researchers on policy content methodology, advocates who can use results for targeted lobbying efforts, and policy makers who may find state comparisons useful for work in their home state.
Impacts of the Medicaid Fee Bump on Access and Provider Behavior
Concerns around access to care, disparities, and quality of care are associated with low Medicaid payments rates in the literature. This project will study the impact of the “Medicaid fee bump,” a 2013-14 increase in primary care reimbursement rates designed to increase access to care for the Medicaid population.
This policy cost the federal government more than $7.1 billion and more than doubled payment rates in some US states (although much less in others), but has been studied in only one published paper to date.
We will use Medicaid MAX claims data and proprietary managed care claims data to study the impacts of the fee bump on:
- provider-level measures of revenue, access, behavior, and Medicaid participation, and
- beneficiary-level measures of access and health care disparities.
The data will span up to 18 states in the managed care data, up to 20 states in the MAX data, or 32 states combined.
Click here to learn more about other available funding opportunities.